Celltrion To Begin Denosumab Trials Within Days
Plans To Complete Trials Before Prolia’s Patent Expires
Celltrion has announced plans to proceed to Phase I clinical trials of its Prolia/Xgeva (denosumab) biosimilar candidate. The company is also working on biosimilar versions of bevacizumab, omalizumab and ustekinumab for both Europe and the US.
